Cytokinetics' royalty update with Royalty Pharma leads Jefferies to cut stock PT

On Thursday, Jefferies made an adjustment to the financial outlook for Cytokinetics (NASDAQ:), reducing the price target to $85.00 from the previous $95.00, while still recommending the stock as a Buy.

The revision follows Cytokinetics’ announcement of a significant capital raise and changes to its financial arrangements with Royalty Pharma, including an updated royalty framework for aficamten (formerly known as CK-3773274 or afi), a loan connected to the Omecamtiv mecarbil confirmatory trial, and additional funding for CK-136 (also referred to as ‘586) along with an equity purchase.

The rationale behind the price target reduction stems from several factors highlighted by Jefferies: increased royalty payments, the debt incurred and related interest expenses, a rise in research and development spending, and the dilution of shares resulting from the capital raise.

Despite these challenges, Jefferies anticipates a more favorable outlook for Cytokinetics in the second half of the year.

The investment firm is looking ahead to several potential catalysts for the biopharmaceutical company, including a mid-year meeting with the Risk Evaluation and Mitigation Strategy (REMS) program, the MAPLE study, and Phase 3 results for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM). These upcoming events are expected to be significant drivers for Cytokinetics’ stock performance.

InvestingPro Insights

As Jefferies adjusts its financial outlook on Cytokinetics, insights from InvestingPro provide additional context for investors. With a market capitalization of $6.21 billion, Cytokinetics has shown a large price uptick over the last six months, boasting an impressive 85.62% return. This performance aligns with the company’s strong return over the last five years, which is a key indicator of its growth trajectory.

However, the company faces challenges as analysts anticipate a sales decline in the current year and do not expect the company to be profitable this year. The gross profit margin stands at a concerning -8755.86% for the last twelve months as of Q1 2024, underscoring the issues with profitability. Moreover, the company’s revenue has seen a sharp decline of -96.17% over the same period.

For investors seeking a deeper analysis, there are additional InvestingPro Tips available for Cytokinetics, including insights on the company’s debt levels and liquidity. With a moderate level of debt and liquid assets exceeding short-term obligations, the financial health of the company may offer some reassurance despite the lack of profitability. InvestingPro users can find out more about these aspects and other metrics by exploring the full list of 11 additional tips on the platform.

For those interested in leveraging these insights to make informed investment decisions, using the coupon code PRONEWS24 can provide an additional 10% off a yearly or biyearly Pro and Pro+ subscription to InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


This website uses cookies. By continuing to use this site, you accept our use of cookies.